Paige links with Flagship on biomarker analysis tools

By staff writers

February 18, 2022 -- Pathology artificial intelligence (AI) software developer Paige has inked a partnership with Flagship Biosciences that makes Flagship's diagnostics software application for immunohistochemistry tissue samples available through the Paige Platform.

Users of Paige Platform will be able to directly launch Flagship's TissueInsight software for quantifying programmed cell death ligand 1 (PD-L1) expression in immunohistochemistry tissue samples. TissueInsight gives CLIA-reportable PD-L1 results, as well as data about the tumor microenvironment, such as information about macrophages and tumor-infiltrating lymphocytes.

TissueInsight automatically reads tissue slides to provide rapid tissue interpretations, according to the company, eliminating the variability of subjective manual tissue scoring. By making the application available through Paige Platform, pathologists will get access to biomarker testing results that will inform treatment planning, the companies said.

Users of Paige Platform will be able to launch Flagship
Users of Paige Platform will be able to launch Flagship's TissueInsight application directly. Image courtesy of Paige.
Paige partners with Mindpeak for AI breast cancer software
Paige and Mindpeak have announced a distribution partnership that will enable pathologists to use Mindpeak's BreastIHC artificial intelligence (AI) software...
Paige appoints new executives
Artificial intelligence software developer Paige announced that it has appointed new executive leaders, including Andy Moye, PhD, as CEO and Jill Stefanelli,...
Paige AI software gets U.K. medtech innovation evaluation
The U.K.'s National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on Paige's Paige Prostate artificial...
FDA clears 1st prostate pathology AI software application
The U.S. Food and Drug Administration (FDA) has authorized marketing of's Paige Prostate artificial intelligence (AI) software, the first prostate...
Paige lands CE Marks for breast, prostate cancer software
Pathology artificial intelligence software developer Paige has received the CE Mark for two software applications, its breast cancer detection software...

Copyright © 2022

Last Updated bc 2/22/2022 7:46:18 AM